A Trial of ABI-007 in Patients With Advanced Non-Hematologic Malignancies

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

20 participants

Study Classification

INTERVENTIONAL

Study Start Date

2000-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This trial will treat patients with advanced (metastatic) cancer with a new chemotherapeutic agent that may be more readily tolerated than some standard therapies. Patients will be given the new chemotherapeutic medicine once a week, by intravenous route, for three weeks, followed by a rest week. Treatment will be repeated in four week cycles if the patient improves on the therapy, and if there are no adverse events that require withdrawal of medication.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This will be a dose-escalating study. ABI-007 will be administered as an outpatient infusion for three weeks followed by a week of rest. The treatment course will repeat every 28 days. No pretreatment will normally be considered necessary. Patients will have white blood cell and platelet counts monitored as will indications of performance (Karnofsky Performance Status), and will be asked to describe adverse events, if present. Patients will be treated for a minimum of two cycles to be evaluable for the study, and may continue in the study for four cycles within the study, if tumor response and safety parameters warrant continuing. Patients may continue on study medication beyond this at the investigator's discretion.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Neoplasms Metastases, Neoplasm

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Cancer solid tumor Advanced malignancy Taxane therapy Biopsy-proven diagnosis of advanced malignancy Various solid tumors which are refractory

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

ABI-007

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* At least 18 years of age
* Life expectancy of at least 2 months
* Off all therapy for at least 3 weeks prior to study drug administration
* Biopsy-proven diagnosis of advanced malignancy
* Patients with solid tumors who have failed standard therapy
* Karnofsky Performance Status of 70% or 0-2 SWOG Performance Status
* Hemoglobin at least 9
* White Blood Cell count of at least 3000/mm3 with absolute neutrophil count of at least 1500/mm3
* Platelet count of at least 100,000/mm3
* Serum Creatinine less than 2 mg/dL
* Transaminases less than 3X the upper limit of normal
* Patient must provide informed consent
* Serum Bilirubin less than 1.5 mg/dL

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Michael J Hawkins, M.D.

Role: STUDY_DIRECTOR

Celgene Corporation

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Abraxis Bioscience, Inc.

Durham, North Carolina, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

References

Explore related publications, articles, or registry entries linked to this study.

Nyman DW, Campbell KJ, Hersh E, Long K, Richardson K, Trieu V, Desai N, Hawkins MJ, Von Hoff DD. Phase I and pharmacokinetics trial of ABI-007, a novel nanoparticle formulation of paclitaxel in patients with advanced nonhematologic malignancies. J Clin Oncol. 2005 Nov 1;23(31):7785-93. doi: 10.1200/JCO.2004.00.6148.

Reference Type BACKGROUND

PMID: 16258082 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CA-005-0

Identifier Type: -

Identifier Source: org_study_id